Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.4.0.8
Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Current assets:    
Cash $ 11,176 $ 18,102
Receivables 3,851 4,646
Prepaid expenses and other current assets 203 687
Total current assets 15,230 23,435
Property and equipment, net 1,678 1,392
Total assets 16,908 24,827
Current liabilities:    
Accounts payable 4,405 3,767
Accrued clinical trials expenses 378 532
Other accrued liabilities 315 219
Deferred contract revenue 8,427 14,375
Current portion of long-term debt, net of discount   2,500
Total current liabilities 13,525 21,393
Warrant liabilities 1,237 8,240
Royalty liability   8,962
Long-term debt, net of discount   9,360
Total liabilities 14,762 47,955
Commitments and contingencies      
Stockholders' deficit:    
Common stock, at amounts paid-in 279,560 265,986
Additional paid-in capital 21,649 21,014
Accumulated deficit (299,063) (310,128)
Total stockholders' equity (deficit) 2,146 (23,128)
Total liabilities and stockholders' equity (deficit) $ 16,908 $ 24,827